• Hypoparathyroidism is a rare endocrine condition which until recently had no therapeutic hormone replacement 1 .
• The mainstay of current treatment is the use of vitamin D analogues and calcium supplements to maintain serum calcium 1 .
• As a result of complications associated with current therapy, careful monitoring of biochemical and radiological parameters is required.
• The aim of this research is to evaluate current management of hypoparathyroidism of a large cohort against European guidelines 2 with the view to identifying those with sub-optimal control who may benefit from recombinant parathyroid hormone 3 .
• 164 adult patients with hypoparathyroidism were identified .
• A retrospective design was used to analyse data between 2012-2017 including patient demographics, metabolic control, treatment, monitoring and complications.
• • Management of hypoparathyroidism in this large cohort was challenging in terms of achieving metabolic control, monitoring patients and prevention of complications.
• A significant proportion of patients remain symptomatic and have evidence of renal complications.
• This data highlights an unmet need in this population for novel therapies, which may offer improved biochemical and symptomatic control. 
